Kodiak Sciences Inc. (NASDAQ: KOD)

Kodiak Sciences Inc. develops retinal therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform to address unmet needs in retinal diseases. The company focuses on creating next-generation treatments for conditions such as diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration, and macular edema secondary to inflammation. Its pipeline includes clinical-stage product candidates designed for extended durability and improved efficacy through sustained drug delivery in ocular tissues.

Kodiak Sciences Inc. generates revenue primarily through the development and potential commercialization of its investigational medicines, with no current product sales as all candidates remain in clinical stages. The company's lead asset, tarcocimab tedromer (Zenkuda or KSI-301), is an anti-VEGF therapy built on the ABC platform, alongside KSI-501, an anti-IL-6 VEGF-trap bispecific, and KSI-101, a high-strength bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation. Revenue generation is anticipated upon regulatory approval and commercial launch of these therapeutics in major markets such as the United States and Europe.

Kodiak Sciences Inc. operates through the following segments:

• Tarcocimab tedromer (Zenkuda/KSI-301): This segment encompasses the development of an anti-VEGF therapy built on the ABC platform, designed for extended ocular half-life and durable efficacy in retinal vascular diseases. Zenkuda has demonstrated positive results in Phase 3 trials for diabetic retinopathy (GLOW1, GLOW2), retinal vein occlusion (BEACON), and wet AMD (DAYLIGHT), with the ongoing DAYBREAK study evaluating flexible dosing from monthly to every six months. The enhanced 50 mg/mL formulation contains both conjugated and unconjugated antibody to balance immediacy and durability.

• KSI-501: This segment focuses on an anti-IL-6, VEGF-trap bispecific therapy built on the ABC platform, targeting retinal vascular diseases by addressing both VEGF and inflammatory pathways. KSI-501 is being evaluated in the Phase 3 DAYBREAK study for wet AMD, using the same enhanced 50 mg/mL formulation as Zenkuda to support individualized dosing based on disease activity. Preclinical data show KSI-501 inhibits VEGF and IL-6, normalizes the blood retinal barrier, and may offer disease-modifying potential beyond current anti-VEGF monotherapies.

• KSI-101: This segment develops a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI), a condition driven by blood retinal barrier disruption and inflammation. KSI-101 is being evaluated in the Phase 3 PEAK and PINNACLE studies, which are actively enrolling patients at 5 mg and 10 mg dose levels versus sham, with topline data expected in 4Q 2026 and 2Q 2027. The APEX Phase 1b study demonstrated meaningful visual and anatomical gains in both diabetic macular edema and MESI populations, supporting its potential as a unifying therapy for inflammation-driven retinal fluid.

Kodiak Sciences Inc. operates in a competitive retinal therapeutics landscape dominated by established anti-VEGF agents such as Eylea, Avastin, Lucentis, and Vabysmo, which are frequently used for diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The company differentiates itself through its ABC platform, enabling prolonged drug retention in ocular tissues and less frequent dosing, aiming to reduce treatment burden while maintaining or improving visual and anatomical outcomes. Its focus on bispecific and multi-targeted approaches, such as IL-6 and VEGF dual inhibition, positions it to address limitations of current monotherapy standards by targeting broader disease biology.

Kodiak Sciences Inc. serves patients suffering from retinal diseases, including those with diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration, and macular edema secondary to inflammation, with therapies administered by retina specialists in clinical settings such as ophthalmology clinics and retinal care centers. The company's product candidates are intended for use by adult patients requiring intravitreal injections to manage vision-threatening retinal conditions, with no specific named customers disclosed in the filing as all therapeutics remain investigational.